Research programme: small molecule kinase therapeutics - Advenchen Laboratories

Drug Profile

Research programme: small molecule kinase therapeutics - Advenchen Laboratories

Alternative Names: AL 58203; AL 58805; AL 8326

Latest Information Update: 27 Jan 2016

Price : $50

At a glance

  • Originator Advenchen Laboratories
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Aurora kinase B inhibitors; Fibroblast growth factor receptor antagonists; MTOR protein inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Jan 2016 Preclinical trials in Cancer in China (unspecified route) (Advenchen pipeline; January 2016)
  • 27 Jan 2016 Preclinical trials in Cancer in USA (unspecified route) (Advenchen pipeline; January 2016)
  • 27 Jan 2016 Advenchen files an IND application for AL 8326 in China for Cancer before January 2016 (Advenchen pipeline; January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top